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Abstract 
Intraperitoneal cisplatin delivery has recently been shown to benefit ovarian cancer 
patients. Cisplatin-containing poly(lactide-co-glycolide) (PLGA) microspheres have 
been proposed for cisplatin delivery. The drug loading of cisplatin containing 
microspheres produced elsewhere is 3-10 %w. Similar microspheres are reported here 
with a mean diameter of 38.8 µm, and a drug loading of 11.7 %w, but using ethyl 
acetate as a safer solvent. In addition, novel formulations of cisplatin-containing solid 
and hollow PLGA 65:35 (lactide:glycolide) fibres were prepared and are reported here 
for the first time. PLGA hollow fibres were produced by phase inversion with a high 
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drug loading of 27 %w. Mechanistic mathematical models were applied to the cisplatin 
release profiles to allow quantitative comparison of microsphere, solid fibre and hollow 
fibre formulations. The diffusion coefficient of cisplatin eluting from a typical batch of 
PLGA microspheres was 4.8×10-13 cm2 s-1; this low diffusivity of cisplatin in 
microspheres was caused by the low porosity of the polymer matrix. The diffusion 
coefficients of cisplatin eluting from a batch of PLGA solid fibres and hollow fibres 
were 6.1×10-10 and 3.3×10-10 cm2 s-1, respectively. These fibres allowed the controlled 
release of high doses of cisplatin over four days and may represent an improvement in 
slow release technology for treatment of ovarian cancer. 
 
Keywords: cisplatin; poly(lactide-co-glycolide); intraperitoneal; ovarian cancer; fibres; 
mathematical model 
 
Introduction 
Intravenous cisplatin or carboplatin is a popular choice for treating ovarian cancer, in 
combination with drugs such as paclitaxel in some cases [1]. The most active 
compound, cis-dichlorodiammine platinum (II) which has come to be known as 
cisplatin, destroys cancer cells by cross-linking their DNA, which ultimately triggers 
cell death. Despite its adverse side effects, which also include nerve damage and nausea, 
about half of all cancer patients receiving chemotherapy are taking platinum drugs. 
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Another problem with conventional cisplatin delivery is its relatively short lifetime in 
the bloodstream. 
 
A meta-analysis of eight studies investigating intraperitoneal cisplatin or carboplatin as 
an addition to standard treatment following surgery has shown an improvement in 
survival for ovarian cancer patients [1]. PLGA microspheres have been proposed as 
suitable depot devices for sustained cisplatin delivery [2-9]. Microspheres are formed as 
the organic solvent is extracted from an emulsion of the polymer solution into the 
aqueous phase. During solvent extraction some of the drug is able to escape. As a 
consequence, these microsphere have cisplatin loadings of 3-10 %w. A disadvantage of 
microsphere formulations is that small microspheres less than 10 µm are readily 
phagocytosed by immune cells [10, 11]. Phagocytosis of the formulation may increase 
immunotoxicity or reduce the efficacy of tumour killing.  
 
Instead of entrapping drugs in microspheres, drugs can be incorporated into larger scale 
fibres. Fibres with controlled porous layers, allow drug release to occur before the 
biodegradable carrier is reduced to fragments which can be phagocytosed. Meshes of 
electrospun fibres [12] have been investigated for drug release. The drug release from 
these structures has not yet been extensively described. In a previous work, hollow 
fibres filled with drug loaded nanoparticles have been used to control the drug release 
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[13]. They have reported the dexamethasone and methotrexate drug release profiles 
from co-polymers such as poly(lactic acid) and ε-caprolactone. 
 
PLGA was selected for this study because it is biocompatible and biodegradable, 
exhibits a wide range of erosion characteristics, has tuneable porosity and surface area 
properties and most importantly, is a FDA approved polymer [14]. Polyester PLGA is a 
copolymer of poly lactic acid (PLA) and poly glycolic acid (PGA). The presence of 
methyl side groups in PLA makes it more hydrophobic than PGA and hence lactide-rich 
PLGA co-polymers (e.g. 65:35) are less hydrophilic, more suitable for encapsulating 
hydrophilic drugs such as cisplatin, and absorb less water preventing rapid loss of drugs. 
Furthermore, research has demonstrated that PLGA can easily be formulated into the 
drug carrying devices and can encapsulate a wide range of drugs, peptides or proteins 
[14, 15].  
 
Here a new form of PLGA device is proposed to overcome these problems and improve 
drug loading: drug loaded spun solid and hollow fibres of PLGA. For the first time we 
report the incorporation of the drug directly into spun solid and hollow fibres for 
continuous manufacture of cisplatin-containing fibres. Rather than finely dispersing the 
polymer solution in water, it is spun, entering the water bath as a continuous stream. 
The liquid polymer stream hardens to a solid (phase inversion) as the organic solvent 
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diffuses into the water. It is proposed that by controlling the conditions of manufacture 
of these formulations, tailored release profiles could be achieved. In addition, fibres 
offer the benefits of continuous manufacture which may improve reproducibility and 
cost to manufacture compared to the batch manufacture of microspheres. Preliminary 
studies showed that the encapsulation of the hydrophilic drug cisplatin is possible in 
PLGA (lactide:glycolide) fibres; 50:50, 65:35 and 75:25. The PLGA 65:35 hollow fibre 
produced by phase inversion gave the highest drug loading compared to other PLGA 
counterparts and the most suitable controlled drug release profile (in vitro study) for 
cancer care, hence this paper presents the drug depot development using 65:35 PLGA 
system. 
 
Mechanistic models for studying diffusion of small molecules in matrices based on 
Fick's laws of diffusion have been available for some time [16]. With the advent of 
powerful, freely obtainable, open-source software [17], mathematical models can be 
rapidly and effectively applied to drug release profiles to high accuracy using a standard 
desktop computer. Statistical methods can be used to objectively identify optimum 
formulations. 
 
The objectives of this work were (a) to demonstrate the principle that cisplatin fibres 
could be a promising alternative to microspheres and (b) to perform rigorous 
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comparisons between the release profiles provided by the formulations. To this aim, 
mechanistic models were used to estimate the diffusion coefficients of cisplatin in 
microspheres, solid and hollow fibres. 
Materials and methods 
Manufacture of microspheres 
PLGA 65:35 (Alkermes, Birmingham, USA) molecular weight of 90-140 kDa was 
dissolved in ethyl acetate to 15 % by weight of dope. Cisplatin powder (50 % by weight 
of PLGA) (Lianyungang Unionrun Foreign Trade Co., Jiangsu, China) was dispersed 
into this mixture on a rolling bed. Microspheres were manufactured by oil in water 
emulsion using a mechanical homogenizer. Polyvinyl alcohol (1 %w) was used to as a 
suspending agent to lower the interfacial tension between the oil and water. The 
suspension was stirred at room temperature for four hours to allow solvent evaporation 
and microsphere hardening. Microspheres were collected by centrifugation at 1200 g, 
washed with distilled water and filtered. Microspheres were then dried overnight over a 
column of air. 
Manufacture of solid fibres 
Spun fibres were manufactured by extruding polymer/cisplatin dope through a needle of 
the spinneret into a water bath and controlling the phase inversion process. The dope 
consisted of poly(lactide-co-glycolide) (PLGA) dissolved in N-methylpyrrolidone 
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(NMP), also containing powdered cisplatin in suspension. PLGA 65:35 was dissolved in 
n-methyl-2-pyrrolidone (NMP) to 18 % by weight of dope. Cisplatin powder (50 % by 
weight of PLGA) was dispersed into this mixture on a rolling bed in a 20 mL syringe. 
Cisplatin was added at the same time as PLGA (F1a, F1b) or after the PLGA had 
completely dissolved (F2). The dope was then extruded through a spinneret needle at 
1.0 mL min-1 into a water bath. The polymer dope entered the water bath as a 
continuous stream; solvent diffused out of the nascent fibre into the water bath. A 
coagulated PLGA fibre containing encapsulated drug is formed due to the rapid 
partitioning of water-soluble organic solvent from the polymer stream [18]. The fibre 
was collected using a rotating spindle (14 rpm) to draw the fibre into a second water 
bath. Fibres were soaked in distilled water for 1 h before being wrapped around a 
cardboard support and vacuum dried overnight. 
Manufacture of hollow fibres 
Hollow fibres (H1) were manufactured in the same way as solid fibres but were 
extruded through a double bore spinneret rather than through the needle. A spinneret is 
a spinning orifice with two concentric needles [19]. Polymer dope was extruded through 
the outer orifice at 3.3 mL min-1 and distilled water flow through the central orifice at 
1.2 mL min-1creating a central bore with a porous skin layer. Air gap of 5cm and bore 
flow rate of 1.2 ml/min was found to be suitable for encapsulation of cisplatin and 
controlling the porosity of the structure.  
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Scanning electron microscopy 
Cisplatin solid (F1b, F2) and hollow (H1b) fibres were incubated in distilled water. 
After 0, 1, 5 and 21 h the water was aspirated, the samples of fibres were oven dried 
overnight at 30°C. Samples were cut into small sections (0.3 cm), then pressed onto 
carbon tabs on specimen plates. Samples were carbon coated prior to imaging. Scanning 
electron microscopy (SEM) images were recorded using a JEOL JSM 6310 electron 
microscope at 5 keV accelerating voltage. 
Mercury Intrusion Porosimetry 
Pore structures of PLGA microspheres and fibres were investigated by mercury 
intrusion porosimetry (MIP) on a Pascal 140 mercury porosimeter with mercury being 
forced into the pores of the test samples at elevated pressures. 
Backscattered electron imaging 
To find the cisplatin distribution, backscattering maps were performed on a JEOL JSM 
6310 electron microscope at 15-20 keV accelerating voltage. While SEM detects 
secondary electrons which are emitted from the carbon coating of the sample, 
backscattering detects electrons which are reflected directly back from the electron 
beam by the sample if it meets an electron opaque material such as platinum atoms. 
Release of cisplatin from solid and hollow fibres was also examined by digital image 
analysis of SEM and backscattered images. Samples of fibres (each set n=4) were 
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soaked in distilled water at 30°C for 1, 5.6 or 21 hours and oven dried at 30°C 
overnight. Unsoaked fibre samples were also placed in the oven to control the effect of 
temperature. SEM and backscattered images were taken of cross-sections of fibre 
samples (n = 4). In order to calculate the areas, images were analysed using ImageJ.  
X-ray microanalysis mapping 
X-ray microanalysis mapping was performed using a JEOL JSM 6310 electron 
microscope at 5 keV accelerating voltage. X-rays are emitted at characteristic 
frequencies by atoms which are excited by the electron stream. Maps were generated by 
collecting the signal corresponding to X-ray frequencies emitted by platinum and 
chlorine in cisplatin. Co-localised platinum and chlorine suggests that cisplatin is 
present. No additional preparation was required for X-ray analysis following SEM. X-
rays emitted by the excited samples were directly captured in situ using the JEOL 
JXA8600 Superprobe electron probe microanalyser attachment. 
Atomic absorption spectroscopy 
Active unbound cisplatin release from delivery devices was quantified using atomic 
absorption spectroscopy (AAS) at 265.9 nm, the frequency corresponding to platinum 
absorption [20]. The instrument, a Perkin Elmer Model 3110, was manually calibrated 
using a working curve. The dilution series consisted of twelve platinum standards in 
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HCl 2.0 M from 1.000 mg mL-1 to 0.001 mg mL-1. The method was validated by 
dissolving powdered cisplatin in water for comparison with the standard. 
 
Release profiles for microspheres (8 mg mL-1), solid fibres (5 mg mL-1), and hollow 
fibres (5 mg mL-1) were determined in 1 mL of distilled water at 37°C for each 
measurement. At each time point the vials containing microspheres were centrifuged 
500 g for 3 min to pellet the microspheres, allowing the release medium to be aspirated. 
A 0.7 mL aliquot of release medium was analysed using AAS; the remaining liquid was 
discarded. Pre-warmed distilled water (1 mL) was used to replace the release medium 
for the next measurement. Samples were dried using heated ceramic crucibles and 
digested with aqua regia (3 vol concentrated HCl: 1 vol concentrated HNO3) at 105°C 
until near dryness twice. Once dry the samples were dissolved in 1.0 mL HCl, 2 M. 
Each microsphere release experiment was performed in triplicate; the fibres release 
experiments were performed with six replicates. Blank microspheres and fibres were 
manufactured and received equivalent treatment and release conditions as the drug-
loaded formulations. No cisplatin was detected in release medium from any of these 
controls. 
Mathematical models 
The cisplatin release data were analysed using empirical and mechanistic models. 
Cisplatin release profiles from different batches were here compared using non-linear 
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mixed effects modelling [21]. This approach treats the inter-batch and intra-batch 
variation separately.  
 
First order models are also appropriate for use as semi-empirical models for studying 
drug release from depots [22, 23]. It can be assumed that the driving force for mass 
transfer is proportional to the difference between the outer surface concentration and the 
concentration of analyte in an analyte-rich region [24]. Equation 1 describes drug 
release from a depot under sink conditions where the concentration of drug in solution, 
M1(t)/v1, is determined by the amount of drug in the depot, M2(∞), and the release 
constant, k21.  
 
( ) ( ) ( )tkeM
v
tM
21121
1
−−⋅∞=  (1) 
 
For some depot formulations the initial burst of drug release can occur faster than 
predicted by a single first order process. In these conditions equation 1 is not 
appropriate. A skewed drug distribution could arise if drug crystals are preferentially 
encapsulated at or near the surface of the depot. Release would be faster than expected 
if it had been assumed that the drug was homogeneously distributed in the matrix. A 
second exponential term can be added to equation 1 to represent the depot as a slow 
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releasing component of the drug. On the other hand, the three compartment model may 
be more suitable to show the release of two pools of drugs in the fibre into the solution. 
 
However, adding parameters to any model will generally reduce the residual error of the 
fit. Increasing the number of parameters in a model decreases the degrees of freedom. 
The more complex model should not be used unless the improvement in predicting 
power justifies the reduction in degrees of freedom. One effective method for 
determining whether this is true is to calculate Akaike’s Information Criterion (AIC) 
[25]. AIC allows comparison of mathematical models of data by trading off the number 
of parameters used against the residual error. AIC values can only be used to compare 
different models of a dataset, not between datasets. The model with the lowest AIC is 
likely to have the optimum balance between simplicity and good predictive power. AIC 
can be used in conjunction with hypothesis testing methods such as analysis of 
variance/covariance during model comparison. The advantage of AIC is that unlike 
hypothesis testing there is no concern that the sequence of analysis will affect the 
results. 
 
Equation 2 describes drug release from a depot under sink conditions consisting of two 
independently releasing pools. The concentration of drug in solution, M1(t)/v1, is 
determined by the amount of drug in the two pools, M3(∞) and M4(∞) and the release 
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constant of the two pools, k31 and k41 respectively. AIC was used to determine whether 
using the second pool was justified for each dataset. 
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Good mechanistic diffusion models have been derived from Fick’s law. These models 
assume sink conditions to simplify the calculations. Mechanistic models can be used to 
calculate the diffusivity of the drug in the matrix. The diffusivity reflects the properties 
of the matrix ignoring the shape and porosity of the matrix. Differences observed must 
be due to the microscopic differences in the matrix structure.  
 
Equation 3 is the Higuchi model [26] where M(t) is the amount of drug released across 
the exposed area, A, after time t, D is the diffusivity of the drug in the matrix medium, 
M(∞)/V is the total amount of drug (M(∞)) initially present in the matrix per unit 
volume (V) and Cs is the solubility of the drug in the solvent. 
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The Higuchi model can be simplified to obtain a linear model as a function of the square 
root of time with a single parameter related to the diffusivity. As the model is only 
defined for one dimension, the drawback of this method is that the approximation is 
only valid for early release and becomes skewed by complete release profiles. 
 
Fick’s Second Law states that the rate of change of concentration in a matrix is 
proportional to the rate of change of concentration gradient at that point. Using 
boundary conditions and rewriting Fick’s Second Law to define the morphology of the 
depot, a diffusion model can be derived for any regularly shaped device. For spherical 
devices, such as microspheres the amount of drug released (M(t)) is predicted to have 
the form shown in equation 4 [16] where n are the terms in the Taylor series expansion, 
D is the diffusivity of the drug in the matrix, t is time since the start of release and R is 
the radius of the microsphere.  
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The cylindrical model (equation 5) incorporates the geometry of the solid fibre [16]. 
The diffusivity (D) of solid fibres can be calculated assuming that the fibres are 
infinitely long, perfect cylinders with radius, a, equal to the mean radius of the fibre. 
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The Taylor series is calculated using αn as the series of positive roots of the Bessel 
function of the first kind of zero order divided by a (J0(aαn) = 0). 
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For a hollow fibre there are different boundary conditions that must be considered. It is 
assumed that the fibres are infinitely long, perfect hollow cylinders with inner radius, a, 
and outer radius, b. This model (equation 6) incorporates the effect of the release of 
drug from the inner surface of the hollow fibre. The Taylor series is calculated using αn 
as the series of positive roots from the convolution of the Bessel functions of the first 
and second kind of zero order divided by a and b respectively 
(J0(aαn)Y0(bαn) - J0(bαn)Y0(aαn) = 0). 
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More complicated models have been developed incorporating terms for particle size 
distribution or tortuosity of voids in the matrix [27] but the effect of adding additional 
terms to the model is not justified unless large improvements of explanatory power can 
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be made. Models incorporating the effect of polymer degradation have not been 
included in this study as the rate of degradation is slow compared to the rate of drug 
release for this system. 
 
Datasets were fitted to exponential (equation 1), biexponential (equation 2), Fick’s First 
Law [26] (equation 3) and Fick’s Second Law [16] (equation 4, 5 or 6) models using R 
software [17]. Relative fits to the different models were compared using AIC.  
 
Results and discussion 
Depot morphology 
Microspheres, solid fibres and hollow fibres were manufactured as described in the 
methods section and observed using SEM and mercury porosimetry to identify 
morphological features. X-ray microanalysis was used to check that the cisplatin was 
well dispersed in the matrix. 
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Figure 1. SEM image showing PLGA 65:35 microspheres. 
Microspheres which had fractured during freeze drying were observed in some images. Scale bar is 100 
and 10 µm. 
 
PLGA 65:35 microspheres were 10 to 100 µm in diameter (Figure 1a). The median 
particle diameter was 38.8±1.4 µm when measured by laser scattering (data not shown). 
Figure 1b shows a microsphere which had fractured during freeze drying, revealing the 
internal structure. Fractured microspheres were composed of solid matrices with small 
internal pores. Although some pores were connected the majority were discrete. Some 
microspheres appeared to have engulfed other microspheres with shell-like pores 
surrounding some regions of a microsphere. This type of structure reflects the properties 
of the emulsion from which the microspheres were formed. Droplets of oil phase 
dispersed in the aqueous continuous phase could be expected to contain droplets of 
water themselves. The low porosity of these microspheres suggests that diffusion of 
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drug will be slow as there are few aqueous channels to allow paths of lower resistance 
to drug escape.  
 
 
Figure 2. SEM images of PLGA 65:35 fibres and effect of drug release in distilled water. 
SEM images of F2 (a, d, g), F1b (b, e, h) and H1b (c, f, i) fibres before soaking (a, b, c), and after soaking 
for 5 h (d, e, f) and 21 h (g, h, i). Scale bar is 100 µm. (F2) = Solid fibre with cisplatin added to clear PLGA 
solution; F1b = solid fibre with Cisplatin, PLGA and NMP all mixed at once; H1b is hollow fibre. 
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Figure 2 shows a cross-section through PLGA 65:35 solid (F1b, F2) and hollow fibres 
(H1b). The matrices of solid and hollow fibres are similar to each other but different 
from microspheres (Figure 1). This suggests that matrix solidification is different during 
emulsion and phase inversion processes. Since immiscible organic solvents such as 
ethyl acetate partition into the water phase slowly, the matrix of microspheres is well 
formed and solid. Conversely, water-soluble organic solvents such as NMP rapidly 
partition out of the stream of dope. As the polymer loses its solvent and water begins to 
enter the fibre, voids are left in the structure, creating finger-like macro voids with a 
porous skin layer.  
 
An alternative theory of the pore formation is that they are formed during the drying 
process. As more solvent is extracted during phase inversion, the oil phase becomes a 
poorer solvent to the polymer chains. The chains become less extended in solution and 
interact more with each other [28] causing the glass transition temperature to increase. 
Since the glass transition temperature is higher and the polymer chains are moving less, 
the diffusivity of the solvent in the oil phase decreases. This decreases the rate at which 
the solvent is extracted. The outer layer of the droplet solidifies first, leaving a molten 
centre. Depending on how long the droplet is exposed to water the droplets of polymer 
may completely then harden as the remaining solvent dissolves away or retain a viscous 
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liquid centre. When the formulation is vacuum dried the remaining solvent is extracted, 
reducing the volume of the core and causing voids to form. 
 
The pores in the fibre structure act as a faster alternative pathway for cisplatin release 
compared to the more dense structure of microspheres. This may be an advantage for 
fibres since their larger physical size may otherwise hinder drug release too much.  
 
Results of the Mercury Intrusion Porosimetry (MIP) analysis revealed that the hollow 
fibre (porosity of 84.3 ± 0.05%; total pore surface area of 60.28 ± 0.1 m2 g-1) was 33.30 
± 0.5% more porous and has larger total pore surface area than the microspheres 
(porosity of 56.29 ± 0.05 %; total pore surface area of 11 ± 0.1 m2 g-1). The analysis 
indicated that the solid fibre has a porosity of 74.0 ± 0.05% and total pore surface area 
of 65.28 ± 0.1 m2 g-1. While the surface areas of the PLGA hollow and solid fibres were 
as would be expected, the PLGA denser beads showed significantly less surface area 
than would be anticipated, suggesting mercury pressurisation may have some effect on 
fragile pore structure of the beads, therefore it is possible that the pore size determined 
for spheres using MIP may have been skewed. The low porosity of the PLGA spheres 
may also be due to the formation of the denser structure during the emulsion 
polymerisation process and possible deformation of accessible pores by the mercury 
pressurization process. The hollow and solid fibres were shown to have skin average 
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pore diameters of 30.90 ± 0.05 nm and 25.60 ± 0.05 nm, respectively. From their pore 
size distributions, it was seen that the structure of both fibres contained macro-pores 
(pore sizes > 50 nm) and meso-pores (pore sizes between 2 to 50 nm). The denser 
structure of the PLGA spheres was also confirmed by SEM results.  
 
Solid and hollow fibres were analysed by backscattered electron imaging to generate 
high-resolution images of the electron dense regions within the matrix of the fibre. 
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Figure 3. Backscattered electron images of PLGA 65:35 fibres and effect of drug release 
in distilled water. 
Backscattered images of F2 (a, d, g), F1b (b, e, h) and H1b (c, f, i) fibres before soaking (a, b, c), and after 
soaking for 5 h (d, e, f) and 21 h (g, h, i). Sample images correspond to Figure 2. Scale bar is 100 µm.  
(F2) = solid fibre formed with Cisplatin added to clear PLGA solution; F1b = solid fibre formed with 
Cisplatin, PLGA and NMP all mixed at once; H1b is hollow fibre. 
 
Figure 3 shows the backscattered electron images corresponding to the SEM images in 
Figure 2. The area of cisplatin was estimated by setting the threshold of the 
backscattered image to just before random speckles appeared in the threshold mask. The 
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area of the mask helped to estimate the amount of drug present in the fibre qualitatively. 
Examining the proportion of the area of the fibre occupied by a high cisplatin density, it 
could be observed that the amount of cisplatin present decreased with time. 
 
In Figure 4 the normalised area was plotted against soaking time. In this case, a mean 
area was used to calculate the normalised area because each sample was an independent 
sample instead of the same sample measured repeatedly. The cross-section of the fibres 
decreases during drug release (Figure 4). In addition, the area of cisplatin decreases. The 
fibre becomes more hydrophilic as it degrades. This allows water to enter the finger-like 
pores. The shrinkage seen here may be caused by the walls becoming progressively 
crushed by the surface tension between water on opposite pore walls.	  The amount of 
drug loading in the drug delivery matrix seems to have played a significant role on the 
rate and duration of drug release. Matrices having higher drug content possess a larger 
initial burst release than those having lower content because of their smaller polymer to 
drug ratio. 
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Figure 4. Decrease in the area of PLGA 65:35 hollow fibres (H1b) and the strongly 
backscattering area. 
Normalized area (white) and area corresponding to percentage of fibre cross-section containing cisplatin 
(grey) (n = 4). Error bars show standard deviation p = 0.95. 
 
X-ray microanalysis at regions of high backscattered electron density confirmed that 
platinum was present. In addition, solid fibres were analysed by X-ray microanalysis 
mapping to confirm that the signals corresponding to the platinum and chlorine co-
localized across a wider area. 
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Figure 4. (i) SEM and (ii, iii, iv) associated X-ray maps of (a) F1a and (b) F2 PLGA 65:35 
cisplatin solid fibre. 
X-ray maps collected at wavelengths corresponding to platinum (ii) Mβ and (iii) Lα bands and (iv) chlorine 
Kα band. (Scale bar is 100 µm). 
 
Figure 5 shows an SEM (top left) of solid fibre cross-sections and X-ray maps of the 
same area for F1a and F2 fibres. The wavelengths of the X-rays collected correspond to 
the strongest wavelengths of platinum (Mα/Mβ at 2.1 keV and Lα at 9.4 keV) and 
chlorine (Kα at 2.6 keV). Strong platinum and chlorine signals were recorded for F1a 
and F2 fibres but not cisplatin-free fibres (data not shown).  
 
From the co-localisation of peaks at wavelengths corresponding to platinum Mβ and Lα 
bands and chlorine Kα bands in images of F1a and F2 fibres it can be inferred that 
cisplatin is the major electron reflecting species in the fibre. The cross-section of F1a 
shows a few large cisplatin crystals with many smaller particles dispersed throughout 
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the fibre. As for F2 fibres the platinum and chlorine bands overlap but appear as large 
crystals rather than smaller finely dispersed crystals. 
 
Cisplatin was added to the dope early for F1a fibres and late for F2 fibres. In the case of 
solid fibres (F1a, F1b), the dope solution was made by adding cisplatin crystals to 
PLGA polymer pellets and then adding NMP solvent to dissolve the polymer while for 
F2 dope was made by mixing cisplatin to clear PLGA solution. Cisplatin in F1a fibres is 
more finely dispersed than for F2 fibres where individual crystals can be seen. It is 
possible that crystals of cisplatin had time to disaggregate in the F1a dope and become 
well dispersed during the extended mixing period. 
Depot release profiles 
Rigorous statistical modelling of drug release data can facilitate comparison and 
optimization of formulations but such analyses are rarely published by experimentalists. 
The widespread use of desktop computers and the free availability of powerful software 
[17] makes comprehensive statistical analysis within the reach of all investigators. 
The data reported by other groups suggests that cisplatin is stable in aqueous solutions 
hence active cisplatin release profiles for PLGA 65:35 depots were quantified using the 
AAS method reported by Ma et al. [20].	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The cisplatin release profile of PLGA 65:35 microspheres was determined for known 
masses of microspheres in distilled water by atomic absorption spectroscopy. The level 
of batch variation was determined to be low using nonlinear mixed effects modelling 
[21]. This powerful modelling technique treats each independent batch as having a fixed 
deviation from the population mean in addition random errors involved when making 
measurements. Applying the linear driving force (LDF) model (equation 1) using 
nonlinear mixed effects enables population information about the samples to be 
determined, generating estimated standard deviations as well as the values of the model 
parameters: the mass of releasable cisplatin, M2(∞) = 11.3±0.63 mg and the release 
constant, k21 = 5.27±3.23×10-6 s-1 (mean ± standard deviation). These values are similar 
to those calculated using non-linear least squares fitting (Table 1). 
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Figure 6. Cisplatin release from PLGA 65:35 microspheres. 
Cumulative cisplatin release from equivalent of 100 mg of PLGA 65:35 microspheres (M1a-e) into distilled 
water over twenty days (n = 5). Lines show Fick's Second Law model (equation 4). Dashed lines show 
confidence intervals of fit, p = 0.95. 
 
Figure 6 shows cisplatin release from PLGA 65:35 microspheres. These release profiles 
are typical of cisplatin lactide and glycolide polymer microspheres produce by a range 
of different routes reported by other groups [18]. These data are shown here fitted to the 
Fick's Second Law release scheme (equation 4). The mechanistic model derived from 
Fick’s second law for spherical structures had a higher AIC than the empirical models. 
This suggests that other processes than simple diffusion contribute to diffusion from 
microspheres. The diffusion coefficient, D = 4.8×10-12±1.5×10-13 cm2 s-1 was 
determined from D/R2 in equation 4 using the mean microsphere radius of 19.4 µm. In 
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addition, the data were fitted to the other models, equations 1-3 (Table 1). From Higuchi 
kinetics (equation 3) the diffusivity was calculated as 2.0×10-11±8.9×10-15 cm2 s-1 (mean 
± standard error). Higuchi kinetics overestimates the diffusion coefficient of systems 
when using total release profiles. It is derived assuming an infinite depot therefore it is 
only appropriate for describing initial diffusion controlled release. The empirical models 
(equations 1 and 2) had the best explaining power (lowest AIC). This may mean that 
wetting, swelling or degradation of the microspheres may play a role in controlling drug 
release. 
 
Figure 7. Release of cisplatin from PLGA 65:35 solid fibres. 
Cumulative release of cisplatin from equivalent of 100 mg of PLGA 65:35 solid fibres (F1a) into distilled 
water over ten days (n = 3, 6). Solid line shows Fick's Second Law model (equation 5). Dashed lines show 
confidence intervals of fit, p = 0.95. 
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Figure 7 shows cisplatin release from PLGA 65:35 F1a solid fibres. These data are 
shown here fitted to the Fick's Second Law release scheme (equation 5). This model 
was as likely to describe the data (similar AIC, Table 1) as the empirical models 
(equations 1 and 2). This suggests that drug release from solid fibres is controlled by 
diffusion. Fibres manufactured from a dope to which cisplatin was added after the 
polymer had dissolved (F2) had a higher drug loading than the other batches (and 
microspheres) but showed additional variance in the release profile (not shown). Images 
of the cross-section of F2 fibres show heterogeneous distribution of large cisplatin 
crystals in the matrix (Figure 2). The variation observed in the release profile is 
probably caused by this poor dispersion of drug. For the other batches (F1a, F1b) the 
cisplatin was added at the same time as the polymer meaning that the drug had more 
time to become well dispersed.  
 
Analysing F1a fibres using Higuchi kinetics the diffusivity of cisplatin in the fibre 
matrix was 2.7×10-9±2.2×10-12 cm2 s-1 (mean ± standard error). This value is two orders 
of magnitude greater than the diffusivity calculated using Higuchi kinetics for 
microspheres. This difference could be caused by open pores in the fibre allowing faster 
diffusion than would occur in a more dense membrane. The Fick's second law model 
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(equation 5) described the data well and predicted a diffusion coefficient of 
6.1×10-10±1.3×10-10 cm2 s-1.  
 
The release profiles of H1a and H1b fibres were determined as for solid fibres. Figure 8 
shows release of cisplatin from two independently manufactured batches of hollow 
fibres. The release profiles of both batches were similar with high drug loading of over 
20 %w with drug release for 200 h. This timescale of release is similar to that of 
microspheres and solid fibres. H1b fibres had a higher drug loading than H1a fibres. 
Non-linear mixed effects modelling of the linear driving force model (equation 1) 
calculated that the mass of releasable drug in 100 mg fibres was M2(∞) = 23.9±3.1 mg 
and were released at a rate defined by the release constant, k21 = 4.9±0.12×10-6 s-1 
(mean ± standard deviation). Using non-linear least squares to find Crank’s solution for 
a hollow cylinder, diffusivity was 3.3×10-10±3.3×10-11 cm2 s-1 for H1a fibres and 
3.0×10-10±2.8×10-11cm2 s-1 for H1b fibres. 
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Figure 8. Release of cisplatin from PLGA 65:35 hollow fibres. 
Cumulative release of cisplatin from 100 mg of two independent batches of PLGA 65:35 H1a (o) and H1b 
(□) hollow fibres. Lines show Fick's Second Law model (equation 6). Dashed lines show confidence 
intervals of fit, p = 0.95. 
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Table 1. Table of drug release model parameters for PLGA 65:35 microspheres (M1a-e), 
solid fibres (F1a) and hollow fibres (H1a, H1b) 
Parameter values shown ± standard error. * Diffusivity calculated for spherical model from D/R2 using 
R = 19.4 µm. 
 
 
Table 1 shows the calculated parameters for equations 1 to 3 for each of the 
formulations, as well as the derivation of Fick's second law corresponding to the 
formulation morphology. Hollow fibres show superior drug loading over microspheres 
and reproducible release characteristics. The diffusivity of cisplatin in the matrix could 
Equation Parameter M1 F1a H1a H1b 
1 LDF M2(∞) (mg) 11.7±0.24 10.1±0.41 20.8±0.52 27.1±0.44 
LDF k21 (×10-6 s-1)  3.95±0.31 4.06±0.40 5.02±0.33 4.78±0.25 
AIC LDF 372 286 673 542 
2 2LDF M3(∞) (mg) 2.46±0.43 1.99±0.46 2.24±1.03 0.506±0.540 
2LDF M4(∞) (mg) 9.85±0.40 9.88±0.72 19.2±0.95 26.7±0.62 
2LDF k31 (×10-4 s-1) 1.05±0.46 0.475±0.225 1.55±1.59 7.76±34.7 
2LDF k41 (×10-6 s-1) 2.45±0.31 2.05±0.42 3.94±0.53 4.62±0.30 
AIC 2LDF 331 265 667 545 
3 Higuchi k (×10-2 mg s-0.5)  1.10±0.023 1.07±0.031 2.25±0.053 2.95±0.057 
AIC Higuchi 428 328 757 663 
4-6 Fick M(∞) (mg) 12.7±0.41 12.1±0.98 21.8±0.70 27.8±0.74 
Fick D (×10-11 cm2 s-1) 0 0.479±0.015* 61.4±13.3 33.1±3.3 29.9±2.8 
AIC Fick 484 275 668 586 
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be altered by varying the conditions of manufacture of the fibres by altering the 
viscosity of the polymer, the air gap between the spinneret and the water bath, the 
temperature of the polymer and water bath or the rate of fibre draw. These variables will 
alter the rate of partition of the organic solvent into the water bath. The rate of 
partitioning has an affect on the porosity of the fibre. It should also be noted that 
continuous manufacture of hollow fibres is easier to scale up than batch microsphere 
production, meaning that manufacture of therapeutic fibre formulations would be faster, 
cheaper and more efficient than for batch production of microspheres. 
 
It is important to note that some of the cisplatin becomes inactivated in vivo by binding 
of aquated cisplatin to nucleophiles such as glutathione, DNA and proteins and only 
unbound cisplatin is able to cause tumour killing. In order to understand the release 
profile changes of these three drug depots in the physiological environment, model 
proteins have been used to investigate the cisplatin binding targets and the results of the 
findings will be reported in the future. Characterising the profile of concurrent cisplatin 
release from a polymer depot and binding to protein will improve understanding of the 
pharmacokinetics of drug release in the physiological environment. 
Conclusion 
A drug delivery formulation of cisplatin containing poly(lactide-co-glycolide) hollow 
fibres was produced with a drug loading more than twice that of comparable 
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microsphere formulations. The release profiles of batches of drug encapsulated hollow 
fibre were similar with high drug loading of over 27 %w with drug release for 200 h. 
The diffusivity of cisplatin in the fibre matrix was found to be far greater than the 
cisplatin diffusivity in microspheres indicating that high drug release rates could be 
achieved with novel fibre system.	  Powdered hydrophilic or hydrophobic drugs can be 
encapsulated within fibres efficiently with minimum drug loss during the controlled 
phase inversion process. Some difficulties may arise with liquid drug encapsulation and 
merit further investigation.	  
Mechanistic mathematical models were applied to the datasets allowing objective, 
quantitative comparisons of the formulations. These showed that the rate constant of 
cisplatin release was similar for all three formulation morphologies. Cisplatin 
containing hollow fibres have the potential to act as an interesting candidate for 
sustained release studies for palliative care of ovarian cancer and merit further 
investigation.	  	  
Depot delivery of cisplatin to the peritoneum should offer further improvements in 
efficacy with reduced toxicity to patients with this disease. The proposed fibre design 
could be easily adapted to carry other types of drugs or even more than one drug at a 
time, which means that this device would be suitable for targeting most of the tumours 
as well as ovarian cancer.  
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